Vyteris, Inc. (VYTR.OB) Announces Agreement to Merge with MediSync BioServices
Vyteris Inc. is the developer and manufacturer of the first active, ready-to-use drug delivery patch (LidoSite) to receive marketing clearance from the US Food and Drug Administration. The company's proprietary transdermal smart patch technology, which allows for precise dosing, delivers drugs comfortably through the skin using low-level electrical energy. The company today announced that it has executed a definite merger agreement with MediSync Bioservices Inc. A privately-held company, MediSync is focused on the consolidation of niche contract research organizations, site management organizations and related businesses within the highly fragmented $22 billion contract drug development industry. Under terms of the agreement,…